Teva Pharmaceutical Industries Ltd. (TEVA) is on target to increase revenue in Europe by 60 percent, Handelsblatt reported, citing an interview with Rob Koremans, who heads the company’s European business.
Koremans, who plans to increase revenue from 5.7 billion euros ($7.6 billion) at present to more than 9 billion euros, said “everything is going to plan at the moment and even a bit better than expected,” the newspaper reported. Teva plans to introduce as many as 14 drugs in the next few years, Handelsblatt cited Koremans as saying.
-- Editor: Alan Purkiss
To contact the reporter on this story: Julie Cruz in Frankfurt via firstname.lastname@example.org
To contact the editor responsible for this story: Sara Marley at email@example.com